Document Detail

Flecainide in the Wolff-Parkinson-White syndrome.
MedLine Citation:
PMID:  1509995     Owner:  NLM     Status:  MEDLINE    
The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node. Flecainide terminates atrioventricular tachycardia in greater than 80% of cases when given intravenously, and oral therapy prevents clinical recurrences in greater than 60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a beta-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.
I Crozier
Related Documents :
3794115 - Electrophysiologic mechanisms of orthodromic tachycardia initiation during ventricular ...
23728845 - Update on arrhythmogenic right ventricular dysplasia/cardiomyopathy (arvd/c).
1889115 - Atrial fibrillation and flutter with left bundle branch block aberration referred as ve...
19578175 - Mechanism of paroxysmal supraventricular tachycardia with ventriculoatrial conduction b...
17719335 - Usefulness of acoustic cardiography to resolve ambiguous values of b-type natriuretic p...
10522795 - Time-dependent efficacy of initial reperfusion with 2,3 butanedione monoxime (bdm) on r...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  70     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-09-24     Completed Date:  1992-09-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  26A-32A     Citation Subset:  AIM; IM    
Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use
Arrhythmias, Cardiac / chemically induced
Atrial Fibrillation / drug therapy
Flecainide / adverse effects,  therapeutic use*
Heart Conduction System / drug effects*
Pre-Excitation, Mahaim-Type / drug therapy
Tachycardia, Atrioventricular Nodal Reentry / drug therapy
Wolff-Parkinson-White Syndrome / drug therapy*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 54143-55-4/Flecainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide ...
Next Document:  Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.